SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families.
Outstanding Marketing & Sales team with strong penetration across key emerging markets.
Robust alliance management capabilities.
Excellent network of regional partners.
Extensive experience in regulatory process.
Founded in Singapore
SciGen Australia Pty Ltd established
SciGen Korea Ltd established
Gensulin®/SciLin® introduced in Europe
First sales of Gensulin®/SciLin® in Asia
Business operation in Philippines
SciTropin A® launched in Korea
Gensulin®/SciLin® launched in China
Acquired Zometa® from Novartis
SciLin® is to receive MA approval in Brazil